ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Immunosuppressant Medications Use in Patients with Transplant Failure: A Canadian Multi-Centre Prospective Study

G. Knoll1, M. Chassé2, D. Fergusson3, A. A. House4, O. Johnston5, R. Mainra6, D. Baran7, D. Treleaven8, l. senecal9, L. Tibbles10, M. Hebert11, M. Karpinski12, T. Campbell13, T. Ramsay14, J. Kim15, I. Houde16, C. White17, J. Perl15, P. Karnabi18, J. Gill5

1Nephrology, Ottawa Hospital Research Institute, Ottawa, ON, Canada, 2University of Montreal, Montreal, QC, Canada, 3Ottawa Hospital Research Institute, Ottawa, ON, Canada, 4Nephrology, Western University, London, ON, Canada, 5Nephrology, University of British Columbia, Vancouver, BC, Canada, 6Nephrology, University of Saskatchewan, Saskatoon, SK, Canada, 7Nephrology, McGill University, Montreal, QC, Canada, 8Nephrology, McMaster University, Hamilton, ON, Canada, 9Nephrology, Maisonneuve-Rosemont Hospital, Montreal, QC, Canada, 10Nephrology, University of Calgary, Calgary, AB, Canada, 11Nephrology, University of Montreal, Montreal, QC, Canada, 12Nephrology, University of Manitoba, Winnipeg, MB, Canada, 13University of Alberta, Alberta, AB, Canada, 14Ottawa Hospital Research Institute, Ottawa, ON, Canada, 15University of Toronto, Toronto, ON, Canada, 16Laval University, Que´bec, QC, Canada, 17Queen's University, Kingston, ON, Canada, 18Ottawa Health Research Institute, Ottawa, ON, Canada

Meeting: 2022 American Transplant Congress

Abstract number: 772

Keywords: Infection, Panel reactive antibodies, Rejection, Survival

Topic: Clinical Science » Kidney » 35 - Kidney: Cardiovascular and Metabolic Complications

Session Information

Session Name: Kidney: Cardiovascular and Metabolic Complications

Session Type: Poster Abstract

Date: Saturday, June 4, 2022

Session Time: 5:30pm-7:00pm

 Presentation Time: 5:30pm-7:00pm

Location: Hynes Halls C & D

*Purpose: This prospective study determined the association of immunosuppressant medication use with the outcomes of death, hospitalized infection, rejection of the failed allograft, and panel reactive anti-HLA antibodies.

*Methods: Patients were enrolled within 21 days of starting dialysis after transplant failure in 16 Canadian centers and had follow-up visits and measurement of panel reactive antibodies (PRA) at 1,3,6, 12 months and then biannually until death, re-transplant or loss to follow-up.

*Results: 269 patients were followed for a median 558 days. The mean (SD) age was 52(15) years, and 76% had mild or no physical limitation. There were 33 deaths, 143 hospitalized infections and 21 rejections. The mean Class I and Class II PRA increased from 11% to 27% and 25% to 47% respectively. The majority (65%) of patients continued immunosuppressants during follow up, 15% discontinued all immunosuppressants, and 20% discontinued all immunosuppressants except prednisone. In a multivariable model, continuation of immunosuppressants was not associated with an increased risk death (HR = 0.4, 955 CI (0.17-0.93) or hospitalized infection (HR =0.76, 95% CI (0.44-1.34). However, the increase in anti-HLA antibodies did not differ between patients who did or did not continue immunosuppressants and patients who continued immunosuppressants were not protected from rejection of the failed allograft (HR 0.81; 95% CI 0.22 to 2.92).

*Conclusions: Continued use of immunosuppressants was not associated with an increased risk of death or hospitalized infection but was insufficient to prevent sensitization or rejection. The findings challenge recommendations to discontinue immunosuppressants after transplant failure and indicate the need for a controlled trial of immunosuppression use.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Knoll G, Chassé M, Fergusson D, House AA, Johnston O, Mainra R, Baran D, Treleaven D, senecal l, Tibbles L, Hebert M, Karpinski M, Campbell T, Ramsay T, Kim J, Houde I, White C, Perl J, Karnabi P, Gill J. Immunosuppressant Medications Use in Patients with Transplant Failure: A Canadian Multi-Centre Prospective Study [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/immunosuppressant-medications-use-in-patients-with-transplant-failure-a-canadian-multi-centre-prospective-study/. Accessed May 8, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences